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Background
The HIV-1 coreceptor CCR5 and antibodies against it are
relevant for HIV-1 vaccine design and therapy. Antibodies
to the first loop (ECL1) of CCR5 have been identified in
HIV-exposed uninfected individuals (ESN) and in HIV-
positive non-progressing subjects. To better define the
role of anti CCR5 antibodies in blocking HIV infection,
we characterized their role at mucosal level and we
defined the fine epitope mapping. Moreover, we tried to
induce and reproduce this CCR5 specific immune
response in animal model, such as mouse and chicken.
Materials and methods
PBMC, CCR5 transfected cell line and epithelial cells were
used to evaluate HIV blocking activity by CCR5 specific
IgA and IgG. A two chambers system was established to
model HIV-1 infection across the human mucosal epithe-
lium. Moreover, to better define the region recognized by
CCR5-antibodies, a panel of synthetic peptides spanning
the CCR5-loop1 region, displaying Glycine or Alanine
substitutions, was assayed for antibody binding with anti-
CCR5 antibodies from ESN. The mutagenized region of
CCR5 was then used to immunize mice and chicken.
Results
Either serum or mucosal IgA to CCR5 were able to specif-
ically block transcytosis of CCR5- but not CXCR4-strains
across a tight epithelial cell layer by interacting with the
first extracellular loop of the receptor (aa:YAAAQWDF-
GNTMCQ). Noteworthy, antibodies against other regions
of CCR5 had no effect on HIV mediated transcytosis. Ami-
noacidic substitutions in positions Ala95 and Ala96 (A95-
A96) were found to increase antibody-peptide binding in
comparison with wild-type peptide (Phe95-Asp96).
Ala95-96 peptide was shown to induce mouse and
chicken antibodies displaying biological activity at very
low concentrations (ng/ml). Strikingly, chicken antibod-
ies to Ala95-96 specifically recognize human CCR5 mole-
cules, downregulate receptor from lymphocytes, inhibit
CCR5-dependent chemotaxis and prevent infection of
several R5-viruses. Structural characterization by NMR
spectroscopy proved the high flexiblility of isolated
epitopes and suggested that Ala95-96 substitutions deter-
mine a slightly higher tendency to generate helical confor-
mations combined with a lower steric hindrance of the
side chains in the peptides.
Conclusion
These findings may be relevant to understand the way to
induce strong and efficient HIV blocking antibodies able
to protect from infection at mucosal site. Moreover, the
chicken model proves a simple and inexpensive approach
that could be translated into clinical practice.
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